Oral Aleniglipron Reduced Weight at 36 Weeks - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

Objective:

To evaluate the efficacy of once-daily aleniglipron in reducing body weight in adults with obesity or overweight without diabetes.

Approach:
  • Trial Design: A randomized phase 2b double-blind, placebo-controlled trial (ACCESS) conducted at 38 US sites.
  • Participants: 406 adults screened; 230 randomly assigned to aleniglipron (45 mg, 90 mg, 120 mg) or placebo.
  • Endpoints: Primary endpoint was percentage change in body weight from baseline to week 36.
Key Findings:
  • Atwek36simdnboyghcl945102prju8fv
Interpretation:

The study demonstrated significant weight loss with aleniglipron compared to placebo, with a favorable safety profile despite common gastrointestinal side effects.

Limitations:
  • EnrolmtxcusivyadpWhgzbf
Conclusion:

Aleniglipron was associated with significant weight loss in adults with obesity or overweight without diabetes.

Sources:

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

Medical Oddities: A fowl cause of urinary obstruction

A rogue chicken bone, stalled sweat, yoga for IBS, and L-theanine for sleep is break room fodder this week.

Medical Oddities: Sheep wool gets into bone repair

From sheep wool to space guts, cannabis beats to tea: science took a wonderfully weird turn. 

May Lower RFR Signal Repeat Revascularization?

Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.